Amgen's Repatha edges ahead in the EU with CHMP nod
This article was originally published in Scrip
Executive Summary
Amgen has nosed ahead in the race to be first to market in the EU with a PCSK9 inhibitor: its offering evolocumab (Repatha) has been granted a positive opinion by the EU's CHMP at its latest meeting this week.